Session Title: Quick Fire Free Paper Session 01
Session Date/Time: Thursday 26/09/2013 | 08:30-10:30
Paper Time: 08:50
Venue: Hall G1 (Level 2)
First Author: P.Busatto ITALY
Co Author(s): M. Chizzolini G. Beltrame R. Melis M. Ambesi Impiombato
To evaluate the safety and efficacy of Ozurdex (dexamethasone intravitreal implant) 0.7 mg in the treatment of irresponsive diabetic macular edema in vitrectomized eyes.
Department of Opthalmology Civil Hospital S. Maria degli Angeli Pordenone and Ophthalmology Unit Camposampiero and Cittadella Hospitals Ulss 15 Alta Padovana -italy
Twenty seven eyes of 26 patients affected by conventional treatment-resistant macular edema and a history of previous pars plana vitrectomy received a single intravitreal injection of 0.7-mg dexamethasone implant ( Ozurdex). The primary efficacy- outcome measure was the change in central retinal thickness from baseline to week 24 measured by optical coherence tomography. Mean best corrected visual acuity and adverse events evaluation were the best secondary efficacy- outcome.
The mean age of patients was 65.5 years. The mean pretreatment central retinal thickness was 549 microns (range 960-260), while mean post intravitreal injection central retinal thickness, at month 1, 2, 3 , 4, 6 were 270, 236, 222, 205 and 393 microns, respectively. The mean best corrected visual acuity was 0,2 (range 0.01-0.7) in the pre-operative period and improved to a mean value of 0.35, 0.6 and 0.47 after 1,3,6 months respectively. Values were statistically significant at any time .All conjunctival hemorrhage, conjunctival hyperemia, eye pain without increased intraocular pressure and cataract development in 2 phakic eyes were the most common adverse events.
Dexamethasone intra vitreal implant was effective in the treatment of refractory macular edema in previously vitrectomized diabetic patients. The increase of retinal thickness and the reduction in visual acuity after the fifth month of implant require further studies to evaluate long term results.